Johan Tijhuis
Directeur Général chez Specs Compound Handling BV
Profil
Johan Tijhuis has worked as the Chief Executive Officer at Specs Compound Handling BV since 1994.
He is also currently a Non-Executive Director at Oncodrone BV.
Postes actifs de Johan Tijhuis
| Sociétés | Poste | Début |
|---|---|---|
Oncodrone BV
 Oncodrone BV BiotechnologyHealth Technology Oncodrone BV develops novel therapeutics for epithelial derived malignancies including prostate, breast, lung, pancreas and bladder cancer. It focuses on developing novel therapeutics for advanced cancer by targeting: Epithelial-to-Mesenchymal Transition (EMT) and Androgen Receptor (AR) Signaling. The company was founded in 2013 and is headquartered in Nijmegen, the Netherlands. | Directeur/Membre du Conseil | - |
Specs Compound Handling BV
 Specs Compound Handling BV Wholesale DistributorsDistribution Services Specs Compound Handling BV provides compound management services. It supplies research compounds to the life science industry. The firm offers services from its two main logistic centers in The Netherlands and Maryland, USA. The company was founded in 1987 and is headquartered in Zoetermeer, the Netherlands. | Directeur Général | 01/08/1994 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Specs Compound Handling BV
Specs Compound Handling BV Wholesale DistributorsDistribution Services Specs Compound Handling BV provides compound management services. It supplies research compounds to the life science industry. The firm offers services from its two main logistic centers in The Netherlands and Maryland, USA. The company was founded in 1987 and is headquartered in Zoetermeer, the Netherlands. | Distribution Services |
Oncodrone BV
Oncodrone BV BiotechnologyHealth Technology Oncodrone BV develops novel therapeutics for epithelial derived malignancies including prostate, breast, lung, pancreas and bladder cancer. It focuses on developing novel therapeutics for advanced cancer by targeting: Epithelial-to-Mesenchymal Transition (EMT) and Androgen Receptor (AR) Signaling. The company was founded in 2013 and is headquartered in Nijmegen, the Netherlands. | Health Technology |
